EdiGene adds lab, office space for R&D center

By The Science Advisory Board staff writers

November 2, 2021 -- Biotech company EdiGene has signed a lease for 14,000 sq ft of lab and office space for its U.S. R&D center in the greater Boston area.

The center will work to translate EdiGene's gene editing technologies into new therapies for serious genetic diseases and cancer, according to the vendor.

If you like this content, please share it with a colleague!

Related Reading

EdiGene raises $62M to expand gene editing technologies
Biotech company EdiGene has raised $62 million in financing to expand its genome editing technologies and to accelerate drug discovery and therapies.

EdiGene, Immunochina to develop CAR-T therapy
EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.